Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Now You See It, Now You Don’t

January 28, 2019 0

Now You See it, Now You Don’t Deliberate Omissions of Real Facts Real facts might be …

End of the Year Decisions Part 2

January 24, 2019 0

Prohost Letter #427 End of the Year Decisions ~ Part 2 As a result of the unexpected …

CompuGen demonstrates the importance of its product COM701 targeting PVRIG in immunotherapy

January 22, 2019 0

Data published in Cancer Immunology Research indicate monotherapy and combination opportunities for COM701, a first-in-class cancer …

Lipocine’s product, LPCN-1144, has promising results in decreasing the risk of NASH in non-alcoholic fatty liver disease

January 17, 2019 0

Lipocine (LPCN), a specialty pharmaceutical company, announced that an approximately eight-week top-line study using LPCN 1144 …

The FDA committee voted 19 to 1 in favor of approving Amgen’s & UCB’s new osteoporosis product Evenity

January 17, 2019 0

On January 8, 2019 the osteoporosis monoclonal antibody Evenity (romosozumab) developed by Amgen and UCB was …

Another drug approval for Exelixis. Why Alnylam’s stock is under pressure today

January 15, 2019 0

More good news came from Exelixis (EXEL). It was expected by many but not by those who …

End of the Year Decisions ~ Part 1

January 15, 2019 1

Prohost Letter #426 End of the Year Decisions ~ Part 1 We decided to make this …

Why the new approval of Exelixis’ blood pressure drug Minnebro in Japan is important

January 9, 2019 0

Exelixis collaborator, Daiichi Sankyo, Receives Regulatory Approval for MINNEBRO™ (Esaxerenone) Tablets for Hypertension in Japan Exelixis …

Japan approved Gilead’s product Epclusa®. See Also: A collaboration agreement with Yuhan

January 8, 2019 0

Gilead Sciences (GILD) has news that begins with an announcement today that Japan’s Ministry of Health, Labour and …

The importance of the FDA granting Fast Track Designation to Vertex’s and CRISPR’s Product CTX-001

January 7, 2019 0

Earlier this month the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for CTX001 for …

Why Loxo Oncology’s and Sage Therapeutics’ stocks staged a Rally today

January 7, 2019 0

Why Loxo Oncology and Sage Therapeutics Have Occupied Today's Headline News LOXO Oncology Eli Lilly (LILY) announced its …

Rhythm Pharmaceutical: Updates on trial results from genetic-derived obesity

January 4, 2019 0

Rhythm Pharmaceuticals, Inc. (RYTM) is a biopharmaceutical company focused on the development and commercialization of therapeutics for …

Bristol-Myers to acquire Celgene. Was this move really a surprise?

January 3, 2019 0

Bristol-Myers Squibb (BMY) will acquire Celgene (CELG) in a cash and stock transaction with an equity value of …

The NEW Prohost Portfolio for 2019

January 3, 2019 0

The NEW Prohost Portfolio Small Important Changes We are making some very small but important changes …

Small firms developing improved CAR T immunotherapy products.

December 28, 2018 0

We have a few small clinical stage firms in the Prohost Portfolio that were established with the …

Gilead: On the road towards realizing its goals. A new collaboration for fibrotic diseases

December 26, 2018 0

Gilead Sciences (GILD) and Scholar Rock Holding Corporation (SRRK) announced entering into a strategic collaboration to discover and develop …

Prohost greetings and opinions

December 24, 2018 0

We Wish You A Happy Spiritual Season and A Happy New Year 2019. We Hope that …

Agenus: Signing a lucrative and rewarding agreement with Gilead

December 20, 2018 0

Agenus (AGEN) announced recently that it entered into an immuno-oncology (I-O) partnership with Gilead Sciences (GILD). …

Proteostasis: Its $100 million agreement with Genentech seems not enough to motivate investors to buy into the stock

December 18, 2018 0

Proteostasis (PTI) signed a worldwide, exclusive license agreement with Genentech about licensing rights to potential therapeutic small …

Great biotech news in a bizarre market. Incyte has two consecutive good news

December 17, 2018 0

During the departed week, outstanding advancements and improvements in various clinical disciplines filled the media. What’s …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Now You See It, Now You Don’t

End of the Year Decisions Part 2

CompuGen demonstrates the importance of its product COM701 targeting PVRIG in immunotherapy

Lipocine’s product, LPCN-1144, has promising results in decreasing the risk of NASH in non-alcoholic fatty liver disease

The FDA committee voted 19 to 1 in favor of approving Amgen’s & UCB’s new osteoporosis product Evenity

Another drug approval for Exelixis. Why Alnylam’s stock is under pressure today

End of the Year Decisions ~ Part 1

Why the new approval of Exelixis’ blood pressure drug Minnebro in Japan is important

Japan approved Gilead’s product Epclusa®. See Also: A collaboration agreement with Yuhan

The importance of the FDA granting Fast Track Designation to Vertex’s and CRISPR’s Product CTX-001

Why Loxo Oncology’s and Sage Therapeutics’ stocks staged a Rally today

Rhythm Pharmaceutical: Updates on trial results from genetic-derived obesity

Bristol-Myers to acquire Celgene. Was this move really a surprise?

The NEW Prohost Portfolio for 2019

Small firms developing improved CAR T immunotherapy products.

Gilead: On the road towards realizing its goals. A new collaboration for fibrotic diseases

Prohost greetings and opinions

Agenus: Signing a lucrative and rewarding agreement with Gilead

Proteostasis: Its $100 million agreement with Genentech seems not enough to motivate investors to buy into the stock

Great biotech news in a bizarre market. Incyte has two consecutive good news